염증 중 백혈구-내피 세포 상호작용을 연구하는 미생리학적 시스템

Executive Industry Relevance

The biomimetic microfluidic assay (bMFA) enables physiologically relevant modeling of leukocyte-endothelial interactions under controlled shear stress and vascular topology, addressing a critical gap in inflammatory disease target validation. By recapitulating the leukocyte rolling/adhesion/migration cascade using human primary cells, the system enhances predictive confidence in preclinical screening of anti-inflammatory therapeutics. This supports early de-risking of therapeutic candidates by linking mechanistic insights to translatable organ-level pathophysiology.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by quantifying neutrophil adhesion and migration in response to inflammatory stimuli such as TNF-alpha.
• Scientific Value: Supports functional target validation through modulation of adhesion molecule expression and endothelial permeability under physiologically relevant flow conditions.
• Scientific Value: Facilitates pathway clarification by correlating spatial adhesion patterns with low shear rate regions and vascular bifurcations identified via CFD modeling.

Screening & Assay Development

• Operational Value: Provides a standardized, reproducible platform for real-time quantification of leukocyte rolling velocity, adhesion frequency, and migration into tissue compartments.
• Operational Value: Enables rapid screening of potential therapeutics using human lung microvascular endothelial cells and primary neutrophils, increasing clinical translatability.
• Operational Value: Supports assay scalability through microfluidic network design derived from in vivo rodent microvascular topology and PDMS microfabrication.

Translational & Preclinical Research

• Translational Value: Uses human-related samples to bridge discovery findings with clinical relevance in inflammatory diseases such as sepsis.
• Translational Value: Measures endothelial integrity via permeability and trans-endothelial electrical resistance (TEER), enabling assessment of barrier function during inflammation.
• Translational Value: Models cell/cell communication critical to organ function, supporting preclinical continuity from target engagement to tissue-level response.

Pipeline & Workflow Integration

The bMFA integrates into the discovery continuum by enabling hypothesis-driven interrogation of leukocyte-endothelial interactions, supporting assay readiness for compound screening, and generating quantitative, imaging-based outputs for data-driven decision-making in lead optimization.

• Discovery Biology: Supports mechanistic de-risking by visualizing spatiotemporal dynamics of neutrophil adhesion and migration under controlled inflammatory stimulation.
• Screening: Delivers quantitative, multiplexed readouts including adhesion maps, migration maps, and endothelial activation states for compound efficacy ranking.
• Analytics: Generates shear rate-correlated adhesion profiles and time-lapse migration data enabling statistical comparison across treatment conditions.
• Translational Research: Connects endothelial activation and neutrophil trafficking to organ-level pathophysiology through permeability and TEER measurements.
• Enterprise Reuse: Establishes a reusable microfluidic platform adaptable to multiple disease models and cell types beyond neutrophil-endothelial interactions.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity in leukocyte trafficking by decoupling shear stress, vascular geometry, and biochemical stimulation in a controlled environment.
• Operational Value: Ensures reproducibility through standardized fabrication, cell seeding under flow, and defined stimulation protocols using TNF-alpha and fMLP.
• Strategic Value: Improves go/no-go decisions by providing early efficacy signals for novel inhibitors such as PKC delta inhibitor in neutrophil migration assays.
• Portfolio Impact: Enables risk-adjusted prioritization of anti-inflammatory candidates based on quantitative inhibition of adhesion and migration in human-relevant systems.

Implementation Considerations

• Requires expertise in microfluidic device fabrication, primary cell culture, and confocal microscopy for image acquisition and analysis.
• Depends on access to syringe pumps, pneumatic priming systems, and CFD simulation tools for shear rate mapping.
• Necessitates standardization across teams for consistent channel coating, cell seeding density, and stimulation timing to ensure data comparability.
• Involves adaptation considerations when extending the model to other vascular beds or cell types due to organ-specific shear profiles and endothelial heterogeneity.
• Limited by the need for meticulous degassing and bubble-free fluid handling to maintain laminar flow and accurate shear stress delivery.

Biopharma FAQs